SOPHiA GENETICS S.A. (SOPH) Company Overview

SOPHiA GENETICS S.A. is a Swiss healthcare technology company listed on Nasdaq under the ticker SOPH. Its core product, SOPHiA DDM, is a cloud-native platform that analyzes genomic and other multimodal health data for hospitals, diagnostic laboratories, and biopharmaceutical companies. The platform does not manufacture sequencers. Instead, it sits above laboratory instruments and converts complex data into standardized analytical results that can support clinical interpretation, research, evidence generation, and drug-development programs.

Many healthcare institutions can sequence samples but lack the bioinformatics teams, validated pipelines, and quality controls needed to run precision-medicine programs at scale. SOPHiA GENETICS packages them into a platform. Its technology principles emphasize machine learning, vendor-neutral architecture, cloud deployment, and compliance-oriented data handling.

Where does the company sit in precision medicine?

Clinical customers use SOPHiA DDM for oncology and inherited-disease workflows; biopharma customers use it for biomarkers, trials, evidence, and potential companion diagnostics. The company reported 528 core genomics customers at December 2025 within a network spanning more than 60 countries. Its company profile frames the mission as expanding access to data-driven medicine—commercially, selling analytics to institutions that do not want to build every capability internally.

The economic engine is usage-based platform revenue. Customers adopt applications and pay according to analysis volumes, access terms, or project scope. Revenue expands when they run more tests, add applications, or enter sponsored biopharma programs. This land-and-expand structure is visible in net dollar retention, which reached 117% in Q1 2026.

How do the three access models work?

Which revenue stream dominates?

The genomics platform supports multiple instruments, specimen types, and disease areas. Revenue still depends on converting signed contracts into live, chargeable analyses.

It does not report operating segments by therapeutic area, so the commercial map is by application and customer type. Oncology is central because complex tumor profiling and liquid biopsy require sophisticated bioinformatics and can generate repeated demand. Rare disease broadens the clinical base; BioPharma turns the network into an evidence asset.

Why is oncology the commercial center?

Oncology offers the clearest expansion path because customers can add solid-tumor, hematology, and liquid-biopsy applications. Q1 2026 included nearly 3,000 liquid-biopsy analyses, while 100 customers across more than 30 countries had signed to adopt MSK-ACCESS or MSK-IMPACT. Implementation speed and recurring volume determine how quickly that interest becomes revenue.

What role do rare disease and BioPharma play?

Rare-disease applications diversify demand and deepen academic relationships. Through its BioPharma offering, the company can support decentralized testing, evidence, biomarkers, and companion diagnostics—making the clinical network more valuable than routine analysis alone.

Q1 2026 showed strong commercial momentum but also the gap between platform growth and profitability. Revenue outpaced analysis growth, retention improved, and gross margin stayed high; operating costs still exceeded gross profit.

Which metrics improved?

Is operating leverage appearing?

The first-quarter release reaffirmed FY2026 revenue guidance of $92M to $94M and an adjusted EBITDA loss of $29M to $32M. The SEC exhibit showed $65.4M of cash. Operating leverage requires revenue to grow faster than research, selling, and administrative expense.

The useful history is the sequence that changed the company from a genomics start-up into a public, multi-application precision-medicine platform. The 2025 annual report connects product expansion, commercialization, and financing to the current strategy.

What changed the business model?

1. 2011
   Formation in Switzerland. The company set out to deliver clinical bioinformatics as a shared platform rather than have every hospital rebuild it.
2. 2014
   First genomics application. Cancer testing established the analysis-based revenue model and initial installed base.
3. 2019
   Radiomics and BioPharma expansion. The strategy broadened toward multimodal data and pharmaceutical partnerships.
4. 2021
   Nasdaq IPO. Public capital funded sales and product development while adding governance requirements.
5. 2022
   SOPHiA CarePath introduced. The vision broadened toward longitudinal, multimodal patient data.
6. 2024
   MSK-powered applications launched. MSK-ACCESS and MSK-IMPACT strengthened liquid-biopsy and solid-tumor offerings.
7. 2026
   Leadership and capital transition. Ross Muken became CEO, Jurgi Camblong moved to Executive Chairman, and equity financing reinforced liquidity.

Each new application and biopharma use case is designed to increase the value of the same analytical core. The unresolved question is whether that breadth can translate into operating leverage.

The moat combines installed workflow, analytical experience, product breadth, and regulatory-quality processes. A hospital that validates an application, trains staff, and integrates reporting incurs switching costs even without an exclusive contract. A network spanning varied instruments and countries also helps demonstrate portability.

Where are switching costs and data advantages?

This scorecard is an interpretation of disclosed facts, not a credit rating. The key resource is the combination of algorithms, curated knowledge, quality systems, clinical validation, deployment expertise, and trust. Patents add protection, but they are only one layer in a fast-moving field.

Which competitors pressure the model?

Customers can build internally, buy point solutions, use instrument-linked software, or outsource testing. SOPHiA GENETICS must prove that an independent platform is more flexible and economical than those substitutes.

SOPHiA GENETICS has a high-gross-margin platform but is not yet self-funding. Gross profit shows attractive unit economics before research, commercialization, administration, litigation, and financing; cash flow shows whether the company can fund them without repeated external capital.

What does the annual balance sheet show?

How should financing be interpreted?

The June offering extended the runway but diluted existing holders. For a DCF, the question is whether the new capital funds growth that ultimately produces durable free cash flow.

No shareholder has majority control, but several concentrated holders sit alongside founder ownership. The disclosed percentages are from February 15, 2026 and predate the June equity issuance.

Which shareholders hold influence?

What changed in the 2026 leadership transition?

The 2026 AGM results confirmed the transition. Governance now separates founder-led technology direction from operating leadership while retaining an independent board majority and lead independent director. Swiss articles generally limit registration of newly acquired voting rights above 15%, subject to exceptions.

Growth rests on converting the installed network into more recurring analyses per customer. U.S. expansion, liquid biopsy, new oncology and exome applications, BioPharma programs, and compute efficiency can reinforce one another: product breadth supports retention, while volume spreads fixed costs.

Which opportunities are most credible?

A June 2026 collaboration memorandum with a leading cancer center illustrates how recognized clinical content can be distributed through SOPHiA DDM. Value depends on implementation and sustained usage, not announcement volume.

What risks deserve the most attention?

Revenue alone does not show platform durability. The best dashboard combines customer acquisition, expansion, usage, margin, and cash consumption, separating recurring growth from project timing or currency effects.

What should researchers monitor each quarter?

Revenue growth versus analysis growth is especially useful. In Q1 2026, revenue rose 22% while analyses increased 16%; the spread may reflect mix, pricing, BioPharma, services, or currency. Researchers should also distinguish reported from adjusted gross margin because amortized development costs remain economically relevant.

Valuation turns on the transition from platform growth to free cash flow. With negative near-term earnings, DCF results are highly sensitive to revenue duration, margins, reinvestment, dilution, and the discount rate.

Which DCF variables drive the story?

Scenario analysis should combine customer productivity, NDR, margin, expense discipline, cash burn, and share count. Management’s profitability targets are milestones to test, not assumptions to accept.